Literature DB >> 30175046

Dilative arteriopathy in Pompe disease may not only affect the cerebral arteries.

Josef Finsterer1.   

Abstract

Entities:  

Keywords:  Arteriopathy; Cardiomyopathy; Intracerebral bleeding; Late onset Pompe disease; Metabolic myopathy; Renal infarction

Year:  2018        PMID: 30175046      PMCID: PMC6116777          DOI: 10.1016/j.ymgmr.2018.08.003

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
With interest we read the article by Pappa et al. about a 42yo male with late onset Pompe disease (LOPD), initially manifesting with progressive, proximal muscle weakness of the lower limbs and later with dilative arteriopathy of the renal artery [1]. The following comments arose. We do not agree with the description of the abnormal MRA as fibromuscular dysplasia [1]. Since smooth muscle cells and the autonomic nerves can be affected in LOPD [2], it is conceivable that the abnormality of the right renal artery represents dilative arteriopathy attributable to the underlying metabolic defect, as has been described for the cerebral arteries [3]. Was dilative arteriopathy detected in any other vascular territory? We also do not agree with the notion that there is a typical gait of LOPD patients [1]. Waddling gait is non-specific and occurs with all myopathies manifesting with weakness of the pelvic girdle or proximal lower limb muscles. LOPD may also manifest in the myocardium as hypertrophic/dilative cardiomyopathy [4]. Was dyspnoea also attributable to involvement of the myocardium leading to heart failure? Which were the findings on echocardiography and cardiac MRI? Did cardiac MRI show late gadolinium enhancement, an indicator for affection of the myocardium in addition to hypertrophy [5]? The patient received enzyme-replacement therapy (ERT) and improved within 2y of treatment with regard to the outcome parameter walking distance. Did ERT also exhibit a beneficial effect on dilative arteriopathy? The patient developed intracerebral bleeding under a double therapy with an antithrombotic agent and oral anticoagulation. Which compounds were actually given? Overall, the case could be more meaningful if arterial biopsy would have been taken, if the effect of ERT on dilative arteriopathy would have been assessed, if the guidelines for treating renal infarction would be revised, and if the patient would have been thoroughly investigated cardiologically.
  5 in total

1.  Stroke in Young-Dilative Arteriopathy: A Clue to Late-Onset Pompe's Disease?

Authors:  Vikram Huded; Vikram Bohra; Jignesh Prajapati; Romnesh DeSouza; Ritesh Ramankutty
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-02-04       Impact factor: 2.136

2.  Dilative Arteriopathy and Leucencephalopathy as Manifestations of a Neurometabolic Disease.

Authors:  Josef Finsterer; Adam Bastovansky
Journal:  Open Neurol J       Date:  2015-06-26

3.  Pompe disease treatment with twice a week high dose alglucoside alfa in a patient with severe dilated cardiomyopathy.

Authors:  Jesa L Landis; Holly Hyland; Steven J Kindel; Ann Punnoose; Gabrielle C Geddes
Journal:  Mol Genet Metab Rep       Date:  2018-05-21

4.  Renal artery fibromuscular dysplasia in Pompe disease: A case report.

Authors:  Evangelia Pappa; Constantinos Papadopoulos; Philippe Grimbert; Pascal Laforêt; Guillaume Bassez
Journal:  Mol Genet Metab Rep       Date:  2018-07-26

5.  Pattern and prognostic value of cardiac involvement in patients with late-onset pompe disease: a comprehensive cardiovascular magnetic resonance approach.

Authors:  Matthias Boentert; Anca Florian; Bianca Dräger; Peter Young; Ali Yilmaz
Journal:  J Cardiovasc Magn Reson       Date:  2016-12-07       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.